Dept. of Biomedical Engineering
Oregon Health & Science University
Cancer is a hypercoagulable state. Thrombosis is the second leading cause of death in cancer, and development of thrombosis confers a worse prognosis for patients with cancer. Conventional anticoagulants are effective at preventing thrombosis (thromboprophylaxis) in patients with cancer, yet thromboprophylaxis is not safe for routine administration in cancer care. A biomarker to identify patients with cancer at risk to develop thrombosis would allow personalized thromboprophylaxis for those in need, while sparing the risks of anticoagulation for those not at elevated risk to develop thrombosis. An increased incidence of thrombosis has been observed in patients with metastatic cancer and acute leukemia. Undifferentiated myeloid leukemia cells are present in the peripheral blood of patients with acute myelogenous leukemia (AML). Thrombosis in AML has been associated with elevated counts of leukemia cells in the peripheral blood. In metastatic cancer, tumor cells are shed into the vascula
School of Medicine
Tormoen, Garth William, "Physical parameters for the procoagulation phenotype of circulating cancer cells" (2013). Scholar Archive. 944.